应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02575 轩竹生物-B
未开盘 05-05 16:08:12
22.140
+0.260
+1.19%
最高
23.220
最低
21.840
成交量
49.14万
今开
21.880
昨收
21.880
日振幅
6.31%
总市值
114.69亿
流通市值
35.58亿
总股本
5.18亿
成交额
1,111万
换手率
0.31%
流通股本
1.61亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
本土商业化提速叠加海外 BD 突破，轩竹生物-B(02575)拓宽确定性增长空间
智通财经 · 04-28
本土商业化提速叠加海外 BD 突破，轩竹生物-B(02575)拓宽确定性增长空间
轩竹生物-B 2025年度收入同比增长72%，多管线布局推动经营亏损大幅收窄
公告速递 · 04-27
轩竹生物-B 2025年度收入同比增长72%，多管线布局推动经营亏损大幅收窄
一周港股牛熊榜 | MANYCORE TECH升逾53%领跑，沪上阿姨、博泰车联强势爆发；轻松健康暴泻67%领跌，诺比侃、派格生物同步走弱
老虎资讯综合 · 04-24
一周港股牛熊榜 | MANYCORE TECH升逾53%领跑，沪上阿姨、博泰车联强势爆发；轻松健康暴泻67%领跌，诺比侃、派格生物同步走弱
港股午评|恒生指数早盘跌1.12% 煤炭股逆市上扬
智通财经 · 04-23
港股午评|恒生指数早盘跌1.12% 煤炭股逆市上扬
港股异动 | 轩竹生物-B(02575)盘中涨超8% NG-350A临床1b期FORTRESS研究初步结果于2026 AACR公布
智通财经 · 04-23
港股异动 | 轩竹生物-B(02575)盘中涨超8% NG-350A临床1b期FORTRESS研究初步结果于2026 AACR公布
港股异动 | 四环医药(00460)涨近3% 附属轩竹生物(02575)于AACR展示相关地罗阿克一线治疗研究数据
智通财经 · 04-21
港股异动 | 四环医药(00460)涨近3% 附属轩竹生物(02575)于AACR展示相关地罗阿克一线治疗研究数据
智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨
智通财经 · 04-21
智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨
轩竹生物-B(02575)：地罗阿克一线治疗ALK阳性晚期非小细胞肺癌III期临床研究数据于2026年AACR展示
智通财经 · 04-19
轩竹生物-B(02575)：地罗阿克一线治疗ALK阳性晚期非小细胞肺癌III期临床研究数据于2026年AACR展示
四环医药：获联交所批准轩竹生物H股全流通
南方财经网 · 04-17
四环医药：获联交所批准轩竹生物H股全流通
轩竹生物-B(02575)：联交所批准建议实施H股全流通的申请
智通财经 · 04-17
轩竹生物-B(02575)：联交所批准建议实施H股全流通的申请
异动解读 | 新适应症III期临床获批，轩竹生物-B盘中大涨6.13%
异动解读 · 04-15
异动解读 | 新适应症III期临床获批，轩竹生物-B盘中大涨6.13%
轩竹生物-B(02575)：安奈拉唑钠新适应症获批开展III期临床试验
智通财经 · 04-15
轩竹生物-B(02575)：安奈拉唑钠新适应症获批开展III期临床试验
轩竹生物-B获批启动安纳拉唑钠根除幽门螺杆菌III期临床试验
美股速递 · 04-15
轩竹生物-B获批启动安纳拉唑钠根除幽门螺杆菌III期临床试验
港股异动 | 轩竹生物-B(02575)午后涨超12% 公司完成H股全流通备案 近期2款自研新药授权出海
智通财经 · 04-14
港股异动 | 轩竹生物-B(02575)午后涨超12% 公司完成H股全流通备案 近期2款自研新药授权出海
全流通备案落地叠加商业化启势，轩竹生物迎流动性与业绩双击
格隆汇 · 04-14
全流通备案落地叠加商业化启势，轩竹生物迎流动性与业绩双击
轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书
智通财经 · 04-12
轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书
港股异动 | 轩竹生物-B(02575)早盘涨超10% 与Boston Oncology就轩悦宁、轩菲宁订立许可及供货协议
智通财经 · 04-10
港股异动 | 轩竹生物-B(02575)早盘涨超10% 与Boston Oncology就轩悦宁、轩菲宁订立许可及供货协议
轩竹生物-B更新3月股份变动月报表，股本保持不变
公告速递 · 04-09
轩竹生物-B更新3月股份变动月报表，股本保持不变
轩竹生物-B达成协议：集团将获超1亿美元付款及销售分成
美股速递 · 04-09
轩竹生物-B达成协议：集团将获超1亿美元付款及销售分成
轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议
智通财经 · 04-09
轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议
加载更多
公司概况
公司名称：
轩竹生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。
发行价格：
--
{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":22.14,"timestamp":1777968492488,"preClose":21.88,"halted":0,"volume":491416,"delay":0,"changeRate":0.011882998171846506,"floatShares":160701996,"shares":518000000,"eps":-0.6081914785239055,"marketStatus":"未开盘","change":0.26,"latestTime":"05-05 16:08:12","open":21.88,"high":23.22,"low":21.84,"amount":11106259,"amplitude":0.063071,"askPrice":22.14,"askSize":2500,"bidPrice":22.08,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.6024538230661328,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":21.88,"openAndCloseTimeList":[[1777944600000,1777953600000],[1777957200000,1777968000000]],"volumeRatio":0.41438246537371193,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"2630341907","title":"本土商业化提速叠加海外 BD 突破，轩竹生物-B(02575)拓宽确定性增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2630341907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630341907?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:21","pubTimestamp":1777335716,"startTime":"0","endTime":"0","summary":"收入同比大增逾70%，“三驾马车”商业化突破在即......2025年轩竹生物-B顺利步入商业化全面起步阶段，进一步巩固了公司的“造血优势”并通过2025年报业绩传达出的跨越盈亏平衡点的预期。2025商业化全面起步，未来两年突破在即近日轩竹生物2025年年度业绩正式出炉。目前来看，轩竹生物在未来2年已显示出强劲的商业化放量预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121652662","title":"轩竹生物-B 2025年度收入同比增长72%，多管线布局推动经营亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1121652662","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121652662?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:45","pubTimestamp":1777290333,"startTime":"0","endTime":"0","summary":"轩竹生物-B于2025年度在生物医药领域的深度竞争环境下，实现了收入与经营效率的双重提升。根据年报相关章节信息，报告期内公司收入约为51.8百万元人民币，较上年度增长约72.0%，在产品推广与商业化能力增强的推动下，规模有所扩大。同时，全年经营开支约为2.51亿元人民币，同比减少约56.6%，有效的成本管控使得整体亏损幅度显著收窄，年度经营亏损降幅达55.9%，录得约2.46亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B 2025年度收入同比增长72%，多管线布局推动经营亏损大幅收窄","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143173819","title":"一周港股牛熊榜 | MANYCORE TECH升逾53%领跑，沪上阿姨、博泰车联强势爆发；轻松健康暴泻67%领跌，诺比侃、派格生物同步走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1143173819","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143173819?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:11","pubTimestamp":1777025517,"startTime":"0","endTime":"0","summary":"MANYCORE TECH于4月17日登陆港交所，发行价7.62港元，上市首日升超180%。该股近7个交易日累计升幅超102%。4月22日股价大涨25.15%，较40港元招股价升幅突破200%，创上市新高。公司今年以来累计跌幅已达57.39%，市值持续缩水引发抛压。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00068","02575","02632","06636","02565","02889","01384","02661","02589","02635"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629006300","title":"港股午评|恒生指数早盘跌1.12% 煤炭股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2629006300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629006300?lang=zh_cn&edition=full","pubTime":"2026-04-23 12:00","pubTimestamp":1776916850,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌1.12%，跌292点，报25870点；恒生科技指数跌2.31%。港股早盘成交1426亿港元。煤炭股逆势上扬。海外局势呈现高不确定性，煤化工为当前煤炭需求端最具弹性变量。兖煤澳大利亚涨5.15%；兖矿能源涨4.62%。沪上阿姨涨超6%，股东自愿延长禁售期彰显发展信心，26年公司门店扩张可期。中海油服绩后涨超6%，地缘紧张拖累钻井平台作业天数，公司全球竞争力逐步增强。轩竹生物-B涨超6%，NG-350A临床1b期FORTRESS研究初步结果于2026 AACR公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01797","02833","HHImain","600029","02635","01171","09868","02589","601808","600115","BK4588","002490","GWLLY","600188","HSTECH","00670","BK4585","06693","00568","MCHmain","06181","03668","BK1587","HSI","513600","BK1616","03330","603906","YZCAY","02333","02575","BK1110","02883","02465","01055","601633","XPEV","BK1233","600988"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629003905","title":"港股异动 | 轩竹生物-B(02575)盘中涨超8% NG-350A临床1b期FORTRESS研究初步结果于2026 AACR公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2629003905","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629003905?lang=zh_cn&edition=full","pubTime":"2026-04-23 11:01","pubTimestamp":1776913266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B盘中涨超8%，截至发稿，涨8.65%，报28.4港元，成交额1.19亿港元。消息面上，4月20日，轩竹生物-B发布公告，NG-350A临床1b期FORTRESS研究的初步结果于2026年4月20日在2026年美国癌症研究协会年会公布。临床1b期FORTRESS研究为一项开放标签、单臂、多中心临床试验，旨在评估NG-350A联合放化疗用于治疗pMMR LARC成人患者，患者须至少具备一项局部或远处复发风险因素，或合并寡转移性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02575","NG","BK4585","BK4588","BK4017","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096147","title":"港股异动 | 四环医药(00460)涨近3% 附属轩竹生物(02575)于AACR展示相关地罗阿克一线治疗研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096147","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096147?lang=zh_cn&edition=full","pubTime":"2026-04-21 11:32","pubTimestamp":1776742321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药涨近3%，截至发稿，涨2.29%，报1.34港元，成交额1804.28万港元。消息面上，4月20日，四环医药发布公告，集团旗下非全资附属公司轩竹生物已在2026年 4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK4585","02575","BK1191","BK1600","VXUS","BK4588","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629772986","title":"智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2629772986","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629772986?lang=zh_cn&edition=full","pubTime":"2026-04-21 07:28","pubTimestamp":1776727718,"startTime":"0","endTime":"0","summary":"根据2026年4月20日询价申购情况，初步确定的本次询价转让价格为410.34元/股。本次询价转让不通过集中竞价交易方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转让。截至收盘，暗盘交易显示报价333港元，较招股价209.88港元上涨58.66%，每手100股，不计手续费，每手赚12312港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bd99c7d8869305150ea2122170bfd90e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","LU0605514214.HKD","LU0251143458.SGD","LU2097828714.EUR","SG9999002463.SGD","LU0320764755.SGD","LU0259732245.USD","LU1039395188.USD","LU2097828557.USD","LU0607220059.USD","HK0000181112.HKD","LU0140636845.USD","LU1226287529.USD","LU1794554557.SGD","03200","LU0593848301.USD","LU1655091616.SGD","LU0449509016.USD","LU2275660780.HKD","LU2394011477.USD","LU2449936058.SGD","02607","LU2580892789.USD","LU2092937221.SGD","LU0039217434.USD","LU0315179316.USD","IE0032431581.USD","LU2348773727.SGD","SG9999001846.SGD","BK4141","LU1064130708.USD","600941","02575","00451","BK4588","LU0651947912.USD","LU0672654166.SGD","LU2298321311.HKD","LU0823426308.USD","LU0048575426.USD","LU2476274308.USD","BK1129","LU1102505762.USD","LU1997245094.SGD","LU0029875118.USD","03750","BK0224","LU0047713382.USD","LU0326948709.USD","BK4519","LU1188198961.HKD","LU0359202008.SGD","LU1242518857.USD","LU1993786604.SGD","LU2148510915.USD","SG9999002828.SGD","LU2348774022.SGD","LU0269904917.USD","LU1008478684.HKD","LU0370786039.SGD","LU2506951792.HKD","LU0516422440.USD","LU0011963245.USD","LU1102505929.USD","02691","LU0164872284.USD","SG9999000459.SGD","603093","LU0192582467.USD","LU0228659784.USD","LU0463099449.HKD","LU2476274720.SGD","LU0165289439.USD","LU0823437842.USD","LU0823414478.USD","300750","LU1328277881.USD","LU1978683503.SGD","SG9999003461.SGD","LU2424517915.HKD","LU1051768304.USD","LU0312595415.SGD","LU2477742899.HKD","LU2360108059.USD","04335","LU2097828805.USD","06608","IE00BZ08YR35.GBP","LU1769817096.USD","LU2289578879.USD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0072913022.USD","LU0106252389.USD","LU0594300179.USD","IE00B543WZ88.USD","LU1048588211.SGD","03983","LU1939255532.USD","LU0516422366.SGD","LU1770034418.SGD","LU0106259558.USD","LU0314109678.HKD","LU0543330483.HKD","LU2778985437.USD","LU0328353924.USD","LU0880133367.SGD","02476","LU0327786744.USD","LU0828237940.HKD","LU2045819591.USD","LU0128522157.USD","LU1781817850.SGD","LU2238339852.HKD","000756","IE0008368742.USD","BK1147","LU0531971595.HKD","LU0143863198.USD","00719","LU1152091168.USD","IE00B8HQ1Z84.USD","LU1580142542.USD","601607","LU0405327494.USD","LU0823426480.USD","LU0043850808.USD","LU0469268626.HKD","LU1023057109.AUD","LU0106959298.USD","LU2153592121.USD","LU3063872942.SGD","IE00B5MMRT66.SGD","SG9999001903.USD","LU2125910849.SGD","LU1051769294.HKD","LU1820825898.SGD","LU2399975544.HKD","LU0132412106.USD","LU2298322129.HKD","LU1997244956.HKD","LU0261950470.USD","BK4526","BK1554","LU0572944931.SGD","LU0594300419.USD","SGXZ81163826.USD","LU2360107325.USD","LU1861219969.SGD","LU2506952410.USD","LU2041044095.USD","01093","BK1116","IE00B3M56506.USD","BK4585","IE00B031HY20.USD","IE00B29SXG58.USD","LU0456827905.SGD","SNFRY","IE00BZ08YS42.EUR","LU1808992512.USD","LU0124384867.USD","LU1880383440.USD","LU0516422952.EUR","PLUG","LU1979443071.USD","SG9999001689.USD","IE0008369823.USD","TSLA","LU1880383366.USD","LU0326950275.SGD","LU0509642566.USD","LU0501845795.SGD","LU0516423091.SGD","LU0210526637.USD","LU0359201885.HKD","LU0405327148.USD","LU0235996351.USD","LU2097828474.EUR","LU1861214812.USD","LU0821914370.USD","LU1868838027.USD","LU2357125470.USD","LU0516423174.USD","LU2298064838.USD","LU1997245177.USD","LU1868837565.USD","BK1521","LU1720050803.USD","LU0611395673.USD","CBLUY","LU0149534421.HKD","LU1226287875.USD","LU0505663152.USD","LU0455707207.USD","09696","INTC","LU1515016050.SGD","LU2580892862.HKD","LU0650527681.SGD","BK1154","LU1303224171.USD","LU1969619763.USD","LU0143863784.USD","301200","LU1960683339.HKD","LU2153591404.USD","01866","LU0449515922.USD","LU0531970944.HKD","LU1831875114.USD","LU2294711473.HKD","LU2495084118.USD","SG9999000327.SGD","IE00BPRC5H50.USD","LU1152091754.HKD","LU1721428347.USD","LU0048580855.USD","00941","HK0000181138.USD","LU0502904849.HKD","LU2294711713.HKD","LU0348805143.USD","LU1255011170.USD","BK1610","LU1048596156.SGD","IE00BZ199S13.USD","IE0003795394.USD","LU2152927971.USD","300476","LU0107464264.USD","LU0049853897.USD","LU0979878070.USD","LU0651946864.USD","LU1251922891.USD","LU1807302812.USD","LU1951186391.HKD","LU2506952337.HKD","BK1594","IE0003851619.USD","LU1719994722.HKD","LU2249611893.SGD","LU1226288170.HKD","META","LU1226287792.SGD","LU0724618433.USD","LU1769817179.HKD","BK1515","LU0828237510.HKD","LU2242644610.SGD","LU0067412154.USD","LU1961090484.USD","SGXZ49509284.SGD","LU0254981946.USD","LU1226288253.USD","LU0828238088.HKD","LU1146622755.USD","BK1191","EVS.SI","IE00B8L5B284.USD","LU0072462343.USD","LU0359201612.USD","LU1813983027.USD","LU0302445910.USD","LU2097828631.EUR","SG9999004220.SGD","COIN","LU0823414551.USD","LU0164865239.USD","LU2506952253.HKD","LU0054450605.USD","LU2039709279.SGD","03393","LU0871576103.HKD","SHPMY","00297","LU1242518931.SGD","LU2328871848.SGD","LU0244354667.USD","LU0188438112.USD","002466","LU2125910500.SGD","LU0231483743.USD","LU0214875030.USD","LU1064131003.USD","LU0181495838.USD","LU0048388663.USD","LU0051755006.USD","IE00BD6J9T35.USD","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628615057","title":"轩竹生物-B(02575)：地罗阿克一线治疗ALK阳性晚期非小细胞肺癌III期临床研究数据于2026年AACR展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2628615057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628615057?lang=zh_cn&edition=full","pubTime":"2026-04-19 18:17","pubTimestamp":1776593868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团已在2026年4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。DIAMOND-2研究是一项在中国境内开展的多中心、随机、开放标签的III期临床研究，以克唑替尼作为对照，旨在头对头评估地罗阿克相较克唑替尼在一线治疗ALK阳性晚期NSCLC患者的有效性与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1191","02575","BK4585","BK4008","III","BK4500","BK4588","ALK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628208795","title":"四环医药：获联交所批准轩竹生物H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2628208795","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628208795?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:00","pubTimestamp":1776423600,"startTime":"0","endTime":"0","summary":"南财智讯4月17日电，四环医药（00460.HK）发布自愿公告，香港联合交易所于2026年4月16日批准其非全资附属公司轩竹生物科技有限公司（股份代号：02575.HK）实施H股全流通与转换及上市，涉及35724.58万股H股（即3.57亿股）的上市及买卖。该事项尚需待所有其他相关条件达成后方可完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709115295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1600","BK1593","00460","BK1191","02575","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791182","title":"轩竹生物-B(02575)：联交所批准建议实施H股全流通的申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791182","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628791182?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:32","pubTimestamp":1776414750,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，于2026年4月16日，联交所批准3.57亿股H股上市及买卖(根据建议H股全流通与转换及上市所转换的非上市股份)，惟须待转换及上市的所有其他条件达成后，方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)：联交所批准建议实施H股全流通的申请","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169201089","title":"异动解读 | 新适应症III期临床获批，轩竹生物-B盘中大涨6.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169201089","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169201089?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:37","pubTimestamp":1776217050,"startTime":"0","endTime":"0","summary":"轩竹生物-B(02575)今日盘中股价大幅上涨6.13%，引起了市场的高度关注。消息面上，公司自主研发的创新药安奈拉唑钠肠溶片（商品名：安久卫®）近日获得中国国家药品监督管理局药品审评中心批准，开展用于根除幽门螺杆菌的新适应症III期临床试验。该试验旨在评估含安奈拉唑钠的铋剂四联疗法的有效性与安全性。幽门螺杆菌感染在中国较为普遍，相关治疗药物市场前景广阔。此次关键临床试验的获批，被视为公司核心产品管线的重要进展，有助于拓展其在消化疾病领域的布局，并可能对公司的长期商业价值产生积极影响，从而提振了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627427789","title":"轩竹生物-B(02575)：安奈拉唑钠新适应症获批开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627427789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627427789?lang=zh_cn&edition=full","pubTime":"2026-04-15 06:34","pubTimestamp":1776206064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本集团自主研发的创新药安奈拉唑钠肠溶片近日获得中国国家药品监督管理局药品审评中心批准，开展含安奈拉唑钠肠溶片的铋剂四联疗法根除幽门螺杆菌的III期临床研究。本次安奈拉唑钠新适应症III期临床试验申请获批，有助于拓展产品适应症范围，提升本公司在消化疾病治疗领域的影响力，对本公司长远发展及商业化布局具有重要意义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1191","BK4134","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197349835","title":"轩竹生物-B获批启动安纳拉唑钠根除幽门螺杆菌III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1197349835","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197349835?lang=zh_cn&edition=full","pubTime":"2026-04-15 06:07","pubTimestamp":1776204434,"startTime":"0","endTime":"0","summary":"轩竹生物制药有限公司（简称“轩竹生物-B”）近日获得监管批准，将正式启动其核心产品安纳拉唑钠用于幽门螺杆菌根除治疗的III期临床试验。该阶段试验的启动标志着药物研发进程迈入关键一步，旨在进一步验证其在根除幽门螺杆菌方面的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627492197","title":"港股异动 | 轩竹生物-B(02575)午后涨超12% 公司完成H股全流通备案 近期2款自研新药授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627492197","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627492197?lang=zh_cn&edition=full","pubTime":"2026-04-14 14:07","pubTimestamp":1776146849,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午后涨超12%，截至发稿，涨4.97%，报32.54港元，成交额8071.47万港元。消息面上，轩竹生物公告，公司已获得中国证监会发出的正式备案通知书，完成六名股东持有的合共3.57亿股未上市股份转换为3.57亿股H股的备案。完成后，轩竹生物的流通股份规模有望实现跨越式扩容，流动性得到根本性提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK4585","02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627675114","title":"全流通备案落地叠加商业化启势，轩竹生物迎流动性与业绩双击","url":"https://stock-news.laohu8.com/highlight/detail?id=2627675114","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627675114?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:48","pubTimestamp":1776127733,"startTime":"0","endTime":"0","summary":"近日，轩竹生物完成H股全流通备案。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/9.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4395522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626172948","title":"轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626172948","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626172948?lang=zh_cn&edition=full","pubTime":"2026-04-12 18:04","pubTimestamp":1775988261,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)公布，近日公司接获中国证监会就其申请H股全流通发出的正式备案通知书,据此，公司已完成有关六名股东持有的合共357,245,794股未上市股份按一对一的基准转换为357,245,794股H股的中国证监会备案。该等357,245,794股H股将于完成有关转换及联交所授出上市批准后于联交所主板上市及买卖。通知自中国证监会批准之日(即 2026年3月26日)起12个月内有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215218","title":"港股异动 | 轩竹生物-B(02575)早盘涨超10% 与Boston Oncology就轩悦宁、轩菲宁订立许可及供货协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215218","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626215218?lang=zh_cn&edition=full","pubTime":"2026-04-10 09:31","pubTimestamp":1775784710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超10%，截至发稿，涨9.96%，报34.46港元，成交额341.38万港元。消息面上，轩竹生物-B发布公告，于2026年4月9日，集团(许可人)与Boston Oncology CGT Holding Co. Limited就吡洛西利、地罗阿克订立许可及供货协议(本协议)。根据许可及供货协议，许可人将授予被许可人独占许可，允许其在授权区域开发、注册并商业化吡洛西利与地罗阿克。许可人将根据双方约定的产品供应价格向被许可人供货，以满足两款药品在授权区域内的商业开发活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02575","BK1191","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124835429","title":"轩竹生物-B更新3月股份变动月报表，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1124835429","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124835429?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:31","pubTimestamp":1775727079,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司（股票代码：02575，简称“轩竹生物-B”）于2026年4月9日披露2026年3月股份变动月报表。报告期为2026年3月1日至3月31日，公司股本结构及各类已发行股份数均与上月持平。\n公司H股数量维持在160,701,996股，未上市股份数量为357,245,794股，截至3月底合计已发行股份总数517,947,790股。报告期内，未见新增发行、购回、注销或库藏股变动，亦无涉及期权及股权激励计划的变化。\n公司同时确认继续遵守香港联交所相关上市规则及法律法规规定，符合对于公众持股量的要求。公告由联席公司秘书何成明签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166717383","title":"轩竹生物-B达成协议：集团将获超1亿美元付款及销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1166717383","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166717383?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:37","pubTimestamp":1775723845,"startTime":"0","endTime":"0","summary":"轩竹生物制药集团近日签署一项重要合作协议，根据协议条款，该集团将获得总额超过1亿美元的里程碑付款，并享有后续产品销售特许权使用费。此次合作标志着公司在创新药商业化领域取得突破性进展，资金注入将加速核心管线的临床开发与全球布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626022459","title":"轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626022459","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626022459?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:36","pubTimestamp":1775723762,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，于2026年4月9日，集团(许可人)与Boston Oncology CGT Holding Co. Limited就吡洛西利、地罗阿克订立许可及供货协议(本协议)。根据许可及供货协议，许可人将授予被许可人独占许可，允许其在授权区域开发、注册并商业化吡洛西利与地罗阿克。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.1},{"period":"1month","weight":-0.2872},{"period":"3month","weight":-0.6871},{"period":"6month","weight":-0.6821},{"period":"1year","weight":0.9086},{"period":"ytd","weight":-0.686}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0353},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}